Publication: The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
datacite.rights | restricted | |
dc.contributor.author | Younossi, Zobair | |
dc.contributor.author | Stepanova, Maria | |
dc.contributor.author | Sanyal, Arun J | |
dc.contributor.author | Harrison, Stephen A | |
dc.contributor.author | Ratziu, Vlad | |
dc.contributor.author | Abdelmalek, Manal F | |
dc.contributor.author | Diehl, Anna Mae | |
dc.contributor.author | Caldwell, Stephen | |
dc.contributor.author | Shiffman, Mitchell L | |
dc.contributor.author | Schall, Raul Aguilar | |
dc.contributor.author | McColgan, Bryan | |
dc.contributor.author | Subramanian, G Mani | |
dc.contributor.author | Myers, Robert P | |
dc.contributor.author | Muir, Andrew | |
dc.contributor.author | Afdhal, Nezam H | |
dc.contributor.author | Bosch, Jaime | |
dc.contributor.author | Goodman, Zachary | |
dc.date.accessioned | 2024-12-13T15:47:24Z | |
dc.date.available | 2024-12-13T15:47:24Z | |
dc.date.issued | 2018-12 | |
dc.description.abstract | BACKGROUND & AIMS Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis and NASH-related cirrhosis from a cohort with longitudinal follow-up data. METHODS Patients with cryptogenic cirrhosis or NASH cirrhosis were screened for a clinical trial. Patients with <5% hepatic steatosis regardless of other histologic features were considered to have cryptogenic cirrhosis. Clinico-laboratory data and adjudicated liver-related events (e.g. decompensation, qualification for transplantation, death) were available. RESULTS A total of 247 patients with cirrhosis (55.3 ± 7.4 years, 37% male) were included; 144 had NASH cirrhosis and 103 had cryptogenic cirrhosis. During a median follow-up of 29 (IQR 21-33) months (max 45 months), 20.6% of patients had liver-related clinical events. Patients with NASH cirrhosis and cryptogenic cirrhosis were of a similar age and gender, as well as having a similar body mass index, PNPLA3 rs738409 genotype, and prevalence of diabetes (p >0.05). However, patients with cryptogenic cirrhosis had higher serum fibrosis markers and greater collagen content and α-smooth muscle actin expression on liver biopsy. Compared to cirrhotic patients with NASH, patients with cryptogenic cirrhosis experienced significantly shorter mean time to liver-related clinical events (12.0 vs. 19.4 months; p = 0.001) with a hazard ratio of 1.76 (95% CI 1.02-3.06). CONCLUSIONS Populations with NASH and cryptogenic cirrhosis have similar demographics, but patients with cryptogenic cirrhosis have evidence of more active fibrosis and a higher risk of liver-related clinical events. Thus, we believe these patients belong to the same spectrum of disease, with cryptogenic cirrhosis representing a more advanced stage of fibrosis. LAY SUMMARY Significant liver damage and cirrhosis of the liver may develop without a known cause - a liver disease referred to as cryptogenic cirrhosis. In this work we found that, in the presence of metabolic abnormalities, cryptogenic cirrhosis may actually be a part of the non-alcoholic fatty liver disease spectrum. Yet, it appears to be more progressive than typical non-alcoholic fatty liver disease, leading to advanced liver disease at a faster rate. | |
dc.description.numberOfPages | 6 | |
dc.description.sponsorship | Department for BioMedical Research, Hepatologie Forschung | |
dc.identifier.doi | 10.7892/boris.122127 | |
dc.identifier.pmid | 30144554 | |
dc.identifier.publisherDOI | 10.1016/j.jhep.2018.08.013 | |
dc.identifier.uri | https://boris-portal.unibe.ch/handle/20.500.12422/193267 | |
dc.language.iso | en | |
dc.publisher | Elsevier | |
dc.relation.ispartof | Journal of hepatology | |
dc.relation.issn | 0168-8278 | |
dc.relation.organization | DCD5A442BBC5E17DE0405C82790C4DE2 | |
dc.relation.organization | DCD5A442C6DFE17DE0405C82790C4DE2 | |
dc.subject | Cryptogenic cirrhosis Fatty liver NAFLD NASH Outcomes | |
dc.subject.ddc | 600 - Technology::610 - Medicine & health | |
dc.title | The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. | |
dc.type | article | |
dspace.entity.type | Publication | |
dspace.file.type | text | |
oaire.citation.endPage | 1370 | |
oaire.citation.issue | 6 | |
oaire.citation.startPage | 1365 | |
oaire.citation.volume | 69 | |
oairecerif.author.affiliation | Department for BioMedical Research, Hepatologie Forschung | |
oairecerif.author.affiliation2 | Universitätsklinik für Viszerale Chirurgie und Medizin, Hepatologie | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.date.licenseChanged | 2019-10-22 23:15:06 | |
unibe.description.ispublished | pub | |
unibe.eprints.legacyId | 122127 | |
unibe.journal.abbrevTitle | J HEPATOL | |
unibe.refereed | true | |
unibe.subtype.article | journal |
Files
Original bundle
1 - 1 of 1
- Name:
- 1-s2.0-S0168827818322955-main.pdf
- Size:
- 510.12 KB
- Format:
- Adobe Portable Document Format
- File Type:
- text
- License:
- publisher
- Content:
- published